Moreover, the association between pCR and immune infiltrate was stronger at day 15 than at baseline, both for sTILs and specific immune subpopulations, especially when immune cells intratumour/more proximal to the tumour were considered, pointing out the potential biological role of immune activation after anti-HER2 priming in early HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.